epratuzumab planned trade name lymphocide humanized monoclonal antibody potential uses may found oncology treatment inflammatory autoimmune disorders systemic lupus erythematosus clinical trial relapsed adult acute lymphoblastic leukemia reported initial results published phase ii trial untreated follicular early results phase ii trial diffuse large bcell lymphoma dlbcl manufacturers august announced success early trials started two phase iii clinical trials july phase iii trials sle failed meet primary epratuzumab binds glycoprotein mature malignant bcells elevated bcell receptor bcr proteins associated sle epratuzumabs mechanism action transfers bcr proteins helper cells called effector cells reduces bcell destruction epratuzumabs impact bodys immune via process called sle therapies destroy bcells compromises immune system immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikiepratuzumab